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BACKGROUND: Long non-coding RNA (lncRNA) has emerged as a new avenue of interest 
due to its various biological functions in cancer. Abnormal expression of lncRNA has been 
reported in other malignancies but has been understudied in head and neck squamous cell cancer 
(HNSCC).  
 
METHODS: lncRNA expression was interrogated via qRT-PCR array for 19 HPV-negative 
HNSCC tumor-normal pairs. The Cancer Genome Atlas (TCGA) was used to validate these 
results. The association between differentially expressed lncRNA and survival outcomes was 
analyzed.  
 
RESULTS: Differential expression was validated for 5 lncRNA (SPRY4-IT1, HEIH, LUCAT1, 
LINC00152, and HAND2-AS1). There was also an inverse association between MEG3 expression 
(not significantly differentially expressed in TCGA tumors but highly variable expression) and 3-
year relapse-free survival (RFS). 
 
CONCLUSION: We identified and validated differential expression of 5 lncRNA in HPV-
negative HNSCC. Low MEG3 expression was associated with favorable 3-year RFS, although 
the significance of this finding remains unclear.  
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Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer type 
worldwide and accounts for approximately 350,000 deaths per year 
(1, 2)
. Risk factors such as 
tobacco, alcohol use, and more recently, human papilloma virus (HPV) have been identified as 
etiological factors in the occurrence of HNSCC. Despite advances in the treatment of localized 
HNSCC, approximately half of patients will develop recurrent disease 
(3)
, which is a major 
contributor to patient mortality. In addition, HPV-positive and HPV-negative HNSCC are 
biologically distinct with the latter being associated with poorer prognosis. Unlike other 
malignancies, there are no tools in widespread use that can identify early disease and there is no 
systematic approach that has proven effective in monitoring for early evidence of recurrence. 
Hence, novel markers are needed that appropriately characterize those patients with early stage 
disease as well as identify and characterize the response of individual patient’s treatment. 
While only 1.2% of our DNA sequence encodes proteins, approximately 75% of the 
human genome is capable of being transcribed into RNA 
(4)
, and it has become increasingly 
apparent that RNA plays a diverse and important role in genome integrity through production of 
both proteins as well as non-coding RNA (ncRNA), including long non-coding RNA (lncRNA). 
While the microRNA (miRNA) class of ncRNA have been widely studied in the context of 
cancer, lncRNA, which are larger (> 200 bases and ~1-2 exons in length) 
(5)
 and have a more 
complex secondary/tertiary structure, have recently begun to garner increased attention 
(6)
. This 
is largely due to their diverse biological functions 
(7)
, which can include inhibition of target gene 
transcription, initiation of alternative splicing, generation of protein scaffolding and chromatin 
organization, and alteration of transcription factor activity.  
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Even though 18,000 human long non-coding human transcripts have been catalogued in 
GENCODE v7 
(4)
, the lncRNA Database (http://www.lncrnadb.org), a database of functionally 
annotated eukaryotic lncRNA, only contains information for 127 human lncRNA, highlighting 
the gap in our knowledge of lncRNA biology. Identification of lncRNA transcripts that are 
associated with human diseases and the corresponding pathobiology (e.g. aggressiveness or 
responsiveness to treatment) would therefore provide a welcome means for prioritizing 
functional studies. 
Several lncRNA have recently been reported to be differentially expressed in various 
cancers and to play a role in cancer growth, invasion, epithelial-to-mesenchymal transition, 
motility, and metastatic potential 
(8, 9)
, and as such are increasingly being recognized as having a 
very strong potential as cancer biomarkers 
(10)
. Several recent studies have reported that higher 
expression of lncRNA, such as HOTAIR (HOX antisense intergenic RNA) and Malat-1 
(metastasis associated lung adenocarcinoma transcript 1), is associated with invasion and 
metastasis in various epithelial cancers 
(11-17)
, although the prognostic significance of lncRNA in 
HNSCC has been understudied to date. The aim of this study was to identify differentially 
expressed lncRNA in HPV-negative HNSCC and assess its impact on outcomes in these groups 
of patients.  
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MATERIALS & METHODS 
 
Tumor Samples 
Initial identification of differentially expressed lncRNA in HPV-negative HNSCC was 
conducted using a quantitative real-time PCR (qRT-PCR) array consisting of 84 lncRNA with 
reported involvement in various cancers using paired archival formalin-fixed paraffin-embedded 
(FFPE) tumor tissue and paired adjacent normal squamous tissue from 19 patients treated for 
incident HNSCC at the University of Cincinnati Cancer Institute. Raw RNA-sequencing (RNA-
seq) reads for all available HPV-negative head and neck cancer tumors (n = 444) and all 
available adjacent normal tissue (n = 44) was downloaded from The Cancer Genome Atlas 
(TCGA) for independent validation of significant results.  
 
RT2 lncRNA qPCR Cancer Array 
Total RNA was extracted from each sample using the RNeasy FFPE kit (Qiagen, Valencia, CA), 
and converted to cDNA using the RT2 First Strand kit (Qiagen), according to the manufacturer’s 
respective suggested protocols. The RT2 Profiler lncRNA qPCR Cancer PathwayFinderArray 
(96-well format) was used to profile expression of 84 lncRNA transcripts that have been 
associated with various cancer types. The array also contains 3 reverse transcription controls, 3 
positive PCR controls, a probe for human gDNA contamination, and 5 housekeeping genes for 
normalization: beta actin (ACTB); beta-2 microglobulin (B2M); Ribosomal protein, large, P0 
(RPLP0); 7SK small nuclear RNA (RN7SK); and Small nucleolar RNA, H/ACA box 73A 
(SNORA73A). PCR mastermix was prepared with 250ng of total cDNA and dispensed in 24µl 
aliquots into each RT2 lncRNA PCR Array well. RT-qPCR was performed using an Applied 
Biosystems StepOnePlus
TM
 Real-Time PCR System (ThermoFisher Scientific, Waltham, MA) 
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under the following conditions: 10 min at 95°C using HotStart Taq Polymerase followed by 40 
cycles of 15s at 95°C and 1min at 60°C. A complete list of the 84 lncRNA included on the array 
can be found in Supplemental Table S1.   
 
Differential Expression 
Expression was normalized to the geometric mean of 5 housekeeping control genes: beta actin 
(ACTB); beta-2 microglobulin (B2M); Ribosomal protein, large, P0 (RPLP0); 7SK 
small nuclear RNA (RN7SK); and Small nucleolar RNA, H/ACA box 73A (SNORA73A). 
Differential expression of each lncRNA was described in terms of fold-change for tumor relative 
to adjacent normal tissue based on a one-sample t-test, adjusted for multiple testing by false 
discovery rate (FDR) estimation and Q values using the methods proposed by Benjamini & 
Hochberg (53). Expression was considered significantly differential where Q < 0.10. 
 
Replication Using TCGA RNA-Sequencing Data 
RNA-sequencing (RNA-seq) data in the form of bam files of aligned reads was obtained for head 
and neck cancers in TCGA project where downloaded from the Cancer Genomics Hub. Reads 
not mapped to human genome where aligned to HPV (NC_001526) E6 and E7 viral oncoproteins 
using bowtie aligner 
(18)
. HPV-status was inferred by designating the sample to be from a HPV-
positive tumor if more than 1,000 reads mapped to HPV oncoproteins and HPV-negative tumor 
otherwise. The harmonized read counts for head and neck TCGA samples aligned to lncRNA 
defined in the GDC.h38 GENCODE v22 GTF file were downloaded from NCI Genomic Data 
Commons 
(19)
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Normalized counts (count per million) for each of the 7 lncRNA in each sample were 
calculated using the cpm function in the Bioconductor package edgeR 
(21)
. Since the distributions 
of lncRNA expression were non-linear, differential expression was assessed non-parametrically, 
using the Wilcoxon rank sum test, comparing tumor expression (n = 444) to that of all available 
normal samples (n = 44), and was considered differential where p < 0.05. Median fold-change 
was determined for each tumor by comparing its expression to the median expression of the 
normal samples. A description of the distribution of expression values for the 7 lncRNA in the 
44 adjacent normal samples is provided in Supplemental Table S2.  
 
Survival Analysis Using TCGA Samples 
To visualize 5-year overall survival (OS) and 3-year relapse-free survival (RFS), univariate 
Kaplan-Meier and cumulative incidence (to account for death as a competing risk 
(22, 23)
) 
functions were generated, respectively, comparing curves for low, normal, and high expression 
levels. Discrete multivariable Cox proportional hazards and cumulative incidence models were 
fit to assess 5-year OS and 3-year RFS, respectively, for each of the significant lncRNA, adjusted 
for age, sex, race, smoking status, tumor site, and stage at diagnosis, as established a priori. 
Missing values of model covariates were imputed (m = 20) using multivariate normal regression, 
based on age, sex, stage, and primary tumor site. Log-log plots [i.e. -log(-log (S(t))) vs. log(t)] 
were generated for each model to verify that the proportional hazards assumption was met. 
Statistical analyses were conducted using Stata 13 (Stata Corp, College Station, TX). All 
statistical tests were two-sided, and significance was considered when the unadjusted p < 0.05.  
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The median age for the UC cases (n = 19 tumor-normal pairs) was 64 years, 74% of which were 
male. UC and TCGA sets differed in terms of smoking status (p = 0.01), with fewer non-smokers 
in the UC set, but were comparable in terms of age, sex, race, primary tumor site, AJCC stage 
group, and tumor grade (Table 1). The majority of tumors in both sets originated in the oral 
cavity (63% and 66%, respectively), and presented at an advanced stage (III or IV).  
Eleven of the lncRNA included on the array were not detected in any of the tumor or 
normal samples (Supplemental Table S1). Twenty lncRNA were significantly differentially 
expressed at a nominal p-value < 0.05 (8 upregulated, 12 downregulated). After FDR adjustment, 
7 lncRNA remained significantly differential (Q < 0.10: SPRY4-IT1, HEIH, LUCAT1, 
LINC00152, and HAND2-AS1, MEG3 and TERC; 4 upregulated, 3 downregulated; Table 2). 
Expression of these 7 lncRNA was also significantly differential for 5 of the 7 lncRNA in the 
TCGA validation set (SPRY4-IT1, HEIH, LUCAT1, LINC00152, and HAND2-AS1). It should be 
noted, however, that although MEG3 and TERC were not significantly differentially expressed in 
the TCGA validation set, there was wide variability in terms of expression in both directions (i.e. 
upregulation and downregulation) for individual tumors relative adjacent normal samples 
(Figure 1B). Interestingly, Black patients in the TCGA dataset were significantly more likely to 
exhibit high (> 2-fold) and low (< 0.5-fold) MEG3 expression (Table 3).  
The relationship between each of the 7 lncRNA and 5-year OS and 3-year RFS was 
assessed using the TCGA dataset. Amongst the 7 lncRNA identified, only differing levels of 
Maternally Expressed 3 (MEG3) had an impact on 3 year RFS. Patients with low MEG3 
expression (<0.5 fold change) were found to have a significantly lower 3-year RFS while higher 
MEG3 expression (> 2 fold change) appeared to have better 3-year RFS, although this did not 
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reach statistical significance (Figure 2 and Table 4). We also analyzed the associations between 
the 7 lncRNA and clinical characteristics of HPV-negative HNSCC in the TCGA dataset and 
found that low MEG3 expression was associated with locally advanced disease and low 
expression of HANDS-2AS1 correlated with more locally advanced cancer, although this did not 
appear to have an impact on survival outcomes.  Restriction of the differential expression 
analysis to the 44 tumor-normal pairs in the TCGA validation set yielded similar results (data not 
shown).  
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There is increasing evidence that aberrant expression of lncRNA plays a role in the genesis and 
progression of HNSCC 
(24, 25)
. Through our present study, we were able to identify and validate 5 
differentially expressed lncRNA in HPV-negative HNSCC (SPRY4-IT1, HEIH, LUCAT1, 
LINC00152, and HAND2-AS1). Further, we found that low expression of MEG3 was associated 
with more favorable 3-year RFS, although the significance of this finding is unclear.  
 MEG3 is an long non-coding RNA located at the DLK-MEG3 locus on chromosome 
14q32.3 and is reported to be a tumor suppressor gene, exerting its effect in part through 
interaction with tumor suppressor and master regulator p53 
(26, 27)
. MEG3 has been reported to be 
downregulated in multiple solid tumor types 
(28)
, which is consistent with what we observed in 
our 19 HPV-negative HNSCC tumor-adjacent normal pairs. However, our observed association 
of low MEG3 expression with better 3-year RFS is contrary to what has been reported for other 
solid tumor types 
(29)
 and therefore should be interpreted with caution. In particular, Jia and 
colleagues found that low expression of MEG3 correlated with poorer outcomes in squamous 
cell carcinoma of the anterior tongue, and overexpression of MEG3 inhibited cell proliferation 
and cell cycle progression in SCC-15 and Cal 27 tongue squamous cell carcinoma cell lines 
(30)
.  
 While the other differentially expressed lncRNA transcripts in our study were not 
associated with OS or RFS in the TCGA head and neck tumors, they have been identified as 
potential markers for poor prognosis in other cancer types. SPRY4-IT1, which is located on the 
SPRY4 gene, has been implicated in cell growth invasion and increased apoptosis 
(31)
, and 
elevated expression of SRPY4-IT1 has been associated with poorer outcomes in esophageal 
squamous cell carcinoma, which, like HPV-negative HNSCC, is also strongly associated with 
tobacco and alcohol 
(32)
. Overexpression of HEIH has been reported in hepatocellular carcinoma, 
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where it is an independent predictor for recurrence and survival and interacts with the lysine 
methyltransferase and Polycomb Repressor Complex 2 member Enhancer of Zeste Homolog 2 
(EZH2)
(33)
. Upregulation of both LUCAT1 and LINC00152 have been associated with poorer 
outcomes for non-small cell lung cancer (NSCLC) 
(34, 35)
, and HAND2-AS1 has been reported to 
be upregulated in stage IVS neuroblastoma 
(36)
  but downregulated in metastatic hepatocellular 
carcinoma 
(37)
, with the latter being more in-line with our narrative of lower expression of 
HAND2-AS1 in HPV-negative HNSCC.  
 Strengths of our study include the comprehensive assessment of 84 cancer-associated 
lncRNA and our ability to access raw RNA-seq data from TCGA. This allowed the alignment of 
our data with annotated lncRNA sequences to validate our findings in an independent dataset and 
assess the impact of significantly differential lncRNA on overall and relapse-free survival, and to 
infer HPV-status by aligning to HPV16 E6/E7 viral mRNA transcripts. Our study also has 
several limitations, including the modest sample size of our initial discovery set, which may 
adversely impacted our power to detect smaller effect sizes, increasing the risk of false-negative 
results. However, our use of a stringent FDR-control and validation in an independent set of 
tumors using TCGA data yields high confidence in our significant results. Furthermore, since no 
adjustments were made for multiple comparisons in the survival analyses, we cannot rule out the 
spurious nature of the observed association between MEG3 and RFS. Additionally, use of 
archival FFPE tissue for our discovery set likely attenuated the lncRNA expression levels, which 
could reduce our sensitivity for detection of signal or more subtle differences in expression. Our 
use of the RNeasy FFPE kit, which is specifically engineered to maximize the integrity and 
downstream results for RNA extracted from FFPE 
(38)
,  helps mitigate this issue; it is also notable 
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that 5 of the 7 differentially expressed lncRNA identified with the array were replicated using 
RNA-seq data from fresh tissue, supporting the validity of our findings.  
 
CONCLUSION 
Expression of lncRNA is dysregulated in HPV-negative HNSCC. Specifically, we have 
identified and validated 5 differentially expressed lncRNA: SPRY4-IT1, HEIH, LUCAT1, 
LINC00152, and HAND2-AS1. Additional studies are needed to confirm the potential prognostic 
value of MEG3 expression in HNSCC.   
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Figure 1. Distribution of log(fold-change) in HPV-negative head and neck squamous cell 
carcinoma (HNSCC) tumors relative to adjacent non-malignant squamous tissue for (A) 
University of Cincinnati patients (n = 19 tumor-normal pairs) and (B) HPV-negative tumors (n = 
444) and adjacent normal tissue (n = 44) with RNA-sequencing data through The Cancer 
Genome Atlas (TCGA). The black dashed center line at 0 corresponds to neutral expression and 
blue dashed lines above and below the center line correspond to respective fold changes of 2.0 






Fold-change for the 19 tumors samples in panel A was calculated by comparing the expression of each tumor to its 
paired adjacent normal sample; fold-change for the 444 TCGA tumors in panel B was calculated by comparing the 
expression to the median expression of the 44 adjacent normal TCGA samples.    
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Figure 2. Cumulative incidence function for 3-year relapse-free survival of HPV-negative 
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Table 1.  Clinicodemographic characteristics of HPV-negative head and neck squamous cell carcinoma 









Cincinnati            
(n = 19)
TCGA  
Validation Set         
(n = 444) pdifference
Age 0.28 a
    Years, median (range) 64 (51-86) 61.5 (19-90)
Sex 0.83 b
    Male 14 (74%) 317 (71%)
    Female 5 (26%) 127 (29%)
Race 0.44 b
    White 16 (84%) 355 (83%)
    Black 3 (16%) 44 (10%)
    Other 0 (0%) 30 (7%)
Smoking Status 0.01 b
    Never 1 (5%) 93 (21%)
    Former 15 (79%) 181 (42%)
    Current 3 (16%) 160 (37%)
Primary Tumor Site 0.75 b
    Oral cavity 12 (63%) 294 (66%)
    Pharynx 1 (5%) 41 (9%)
    Larynx 6 (32%) 109 (25%)
AJCC Stage Group 0.68 b
    I 0 (0%) 23 (5%)
    II 2 (11%) 74 (17%)
    III 5 (28%) 82 (18%)
    IV 11 (61%) 265 (60%)
Tumor Grade 0.25 b
    Well differentiated 6 (32%) 59 (13%)
    Moderately differentiated 9 (47%) 276 (63%)
    Poorly differentiated 4 (21%) 96 (22%)
    Undifferentiated 0 (0%) 2 (<1%)
    Undetermined 0 (0%) 8 (2%)
a  Wilcoxon Rank Sum test
b Fisher's Exact test
Abbreviations: 
TCGA = The Cancer Genome Atlas; AJCC = Americal Joint Committee on Cancer
hrHPV = high-risk human papillomavirus
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Table 2. Differentially expressed lncRNA in HPV-negative head and neck squamous cell carcinoma (HNSCC). 
 
Human lncRNA qPCR Cancer Array                                                  
(nT-N pairs = 19) 
TCGA RNA-seq                                 
Replication Set (n = 444) 
lncRNA Ensembl ID 
Median      Fold-
Change p-value Q-value   
Median      
Fold-Change p-value 
SPRY4-IT1 ENSG00000281881 2.19 0.006 0.07 3.52 < 0.0001 
HEIH ENSG00000278970 0.56 0.0001 0.01 0.64 < 0.0001 
LUCAT1 ENSG00000248323 2.14 0.002 0.04 1.76 < 0.0001 
LINC00152 ENSG00000222041 5.11 0.003 0.06 1.56 < 0.0001 
HAND2-AS1 ENSG00000237125 0.47 0.005 0.06 0.13 < 0.0001 
MEG3 ENSG00000214548 0.16 0.0003 0.01 0.33 0.50 
TERC ENSG00000270141 2.32 0.0007 0.02 0.64 0.12 
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Table 3.  Association between expression of significantly differential lncRNA and patients characteristics and clinical features in the TCGA HPV-







Low                       
(n = 89)
High                     
(n = 0)
Low                      
(n = 92)
High                     
(n = 2)
Low                     
(n = 19)
High                     
(n = 291)
Low                     
(n = 6)
High                     
(n = 291)
Low                     
(n = 275)
High                     
(n = 43)
Low                     
(n = 134)
High                     
(n = 107)
Low                     
(n = 189)
High                     
(n = 99)
Age, per decade 1.08 (0.87-1.34) --- 0.75 (0.60-0.94) --- 1.11 (0.65-1.88) 0.99 (0.82-1.21) --- 1.09 (0.83-1.43) 0.87 (0.70-1.08) 0.67 (0.48-0.92) 0.84 (0.68-1.04) 0.93 (0.74-1.16) 1.05 (0.86-1.28) 1.40 (1.08-1.81)
Sex
    Male Reference Reference Reference Reference Reference Reference Reference Reference Reference Reference Reference Reference Reference Reference
    Female 0.72 (0.41-1.26) --- 0.56 (0.30-1.06) --- 0.60 (0.15-2.44) 1.07 (0.64-1.78) --- 0.90 (0.46-1.77) 0.60 (0.35-1.01) 0.62 (0.26-1.47) 1.45 (0.84-2.50) 1.00 (0.55-1.81) 1.36 (0.81-2.30) 0.65 (0.33-1.28)
Race
    White Reference Reference Reference Reference Reference Reference Reference Reference Reference Reference Reference Reference Reference Reference
    Black 1.26 (0.49-3.23) --- 1.15 (0.51-2.58) --- 0.49 (0.06-4.40) 0.74 (0.36-1.50) --- 0.94 (0.35-2.54) 1.16 (0.51-2.64) 1.57 (0.47-5.30) 3.34(1.43-7.80) 2.85 (1.18-6.90) 0.90 (0.41-1.99) 1.05 (0.43-2.57)
    Other 0.97 (0.37-2.58) --- 3.50 (1.47-8.35) --- 0.88 (0.09-8.95) 1.41 (0.54-3.68) --- 0.81 (0.28-2.38) 0.90 (0.37-2.23) --- 0.74 (0.29-1.86) 0.41 (0.13-1.30) 0.85 (0.35-2.09) 1.00 (0.34-2.98)
Smoking status
    Never Reference Reference Reference Reference Reference Reference Reference Reference Reference Reference Reference Reference Reference Reference
    Former 1.27 (0.65-2.45) --- 1.12 (0.53-2.38) --- 0.73 (0.19-2.83) 0.67 (0.36-1.26) --- 0.60 (0.25-1.43) 0.59 (0.45-1.72) 0.54 (0.20-1.47) 1.64 (0.84-3.22) 0.68 (0.35-1.34) 1.57 (0.84-2.90) 1.59 (0.73-3.50)
    Current 1.59 (0.77-3.30) --- 1.37 (0.65-2.91) --- 0.39 (0.07-2.20) 0.79 (0.40-1.54) --- 0.78 (0.30-2.00) 0.59 (0.29-1.20) 0.45 (0.16-1.24) 0.90 (0.44-1.85) 0.53 (0.26-1.08) 1.48 (0.77-2.84) 1.30 (0.56-3.03)
Primary tumor site
    Oral cavity Reference Reference Reference Reference Reference Reference Reference Reference Reference Reference Reference Reference Reference Reference
    Pharynx 1.34 (0.52-3.48) --- 0.53 (0.19-1.47) --- 3.20 (0.83-12.40) 0.61 (0.28-1.29) --- 0.36 (0.14-0.92) 1.08 (0.49-2.40) 0.52 (0.13-2.09) 1.29 (0.58-2.90) 0.92 (0.36-2.32) 1.15 (0.50-2.64) 1.73 (0.67-4.49)
    Larynx 0.82 (0.43-1.54) --- 0.93 (0.50-1.74) --- 1.25 (0.31-5.08) 0.96 (0.55-1.66) --- 0.53 (0.26-1.06) 1.33 (0.74-2.41) 0.48 (0.16-1.47) 0.71 (0.39-1.30) 0.86 (0.46-1.62) 0.56 (0.31-1.01) 1.49 (0.77-2.88)
AJCC Stage Group
    Early (I or II) Reference Reference Reference Reference Reference Reference Reference Reference Reference Reference Reference Reference Reference Reference
    Late (III or IV) 1.09 (0.52-2.28) --- 0.62 (0.28-1.37) --- 2.06 (0.42-10.13) 1.48 (0.78-2.82) --- 1.49 (0.65-3.42) 2.86 (0.74-2.41) 0.75 (0.20-2.81) 1.11 (0.56-2.18) 1.01 (0.48-2.14) 1.84 (0.94-3.60) 0.39 (0.17-0.91)
N classification
    N0 Reference Reference Reference Reference Reference Reference Reference Reference Reference Reference Reference Reference Reference Reference
    N1-3 0.88 (0.47-1.65) --- 1.65 (0.86-3.19) --- 0.47 (0.13-1.71) 0.82 (0.47-1.44) --- 1.25 (0.59-2.63) 0.28 (0.15-0.54) 1.31 (0.39-4.44) 0.49 (0.28-0.88) 0.72 (0.38-1.34) 0.97 (0.56-1.69) 2.68 (1.26-5.69)
Tumor grade
    Low Reference Reference Reference Reference Reference Reference Reference Reference Reference Reference Reference Reference Reference Reference
    Moderate 1.39 (0.66-2.92) --- 1.22 (0.56-2.64) --- 1.87 (0.20-17.04) 1.38 (0.73-2.58) --- 1.34 (0.58-3.13) 1.07 (0.52-2.19) 0.74 (0.25-2.19) 0.83 (0.41-1.66) 1.01 (0.48-2.19) 0.94 (0.48-1.85) 1.17 (0.49-2.81)
    High/undifferentiated 0.64 (0.28-1.46) --- 0.67 (0.26-1.72) --- 7013 (0.78-64.74) 1.22 (0.58-2.58) --- 1.21 (0.45-3.28) 0.87 (0.38-1.96) 0.94 (0.28-3.21) 0.65 (0.29-1.47) 1.33 (0.31-1.85) 0.62 (0.28-1.35) 0.71 (0.26-1.90)
TERCSPRY4-IT1 HEIH LUCAT1 LINC00152 HAND2-AS1 MEG3
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Table 4.  Crude and adjusted hazard ratios (HR) and subhazard ratios (SHR) for the association between 
expression of differentially expressed lncRNA and 5-year overall survival (OS) and 3-year relapse-free survival 





lncRNA expression n Crude HR Adjusted HRa n Crude SHR Adjusted SHRa
SPRY4-IT1
    Low (<0.5-fold) 0 --- --- 0 --- ---
    Normalb 87 1.00 (reference) 1.00 (reference) 54 1.00 (reference) 1.00 (reference)
    High (>2-fold) 352 0.93 (0.62-1.38) 0.89 (0.60-1.34) 218 1.40 (0.63-3.12) 1.30 (0.54-3.13)
HEIH
    Low (<0.5-fold) 92 0.82 (0.54-1.28) 0.88 (0.56-1.36) 59 0.91 (0.45-1.84) 1.14 (0.54-2.40)
    Normalb 345 1.00 (reference) 1.00 (reference) 212 1.00 (reference) 1.00 (reference)
    High (>2-fold) 2 --- --- 1 --- ---
LUCAT1
    Low (<0.5-fold) 18 1.49 (0.67-3.32) 1.61 (0.71-3.68) 12 3.07 (0.84-11.19) 2.58 (0.71-9.33)
    Normalb 131 1.00 (reference) 1.00 (reference) 80 1.00 (reference) 1.00 (reference)
    High (>2-fold) 290 0.92 (0.64-1.31) 0.85 (0.60-1.23) 180 1.50 (0.74-3.02) 1.54 (0.70-3.41)
LINC00152
    Low (<0.5-fold) 8 --- --- 7 --- ---
    Normalb 68 1.00 (reference) 1.00 (reference) 41 1.00 (reference) 1.00 (reference)
    High (>2-fold) 363 0.84 (0.55-1.28) 0.74 (0.48-1.14) 224 1.32 (0.52-3.34) 1.11 (0.41-3.04)
HAND2-AS1
    Low (<0.5-fold) 271 0.92 (0.64-1.31) 0.96 (0.66-1.39) 167 0.87 (0.47-1.64) 0.83 (0.43-1.60)
    Normalb 126 1.00 (reference) 1.00 (reference) 80 1.00 (reference) 1.00 (reference)
    High (>2-fold) 42 0.63 (0.30-1.34) 0.71 (0.33-1.51) 25 0.94 (0.31-2.83) 0.82 (0.25-2.65)
MEG3
    Low (<0.5-fold) 133 1.09 (0.75-1.57) 1.11 (0.76-1.62) 71 0.38 (0.14-1.00) 0.28 (0.10-0.78)
    Normalb 202 1.00 (reference) 1.00 (reference) 127 1.00 (reference) 1.00 (reference)
    High (>2-fold) 104 0.88 (0.56-1.40) 0.84 (0.53-1.34) 74 1.63 (0.89-2.98) 1.43 (0.75-2.74)
TERC
    Low (<0.5-fold) 187 1.01 (0.69-1.47) 0.90 (0.61-1.33) 115 1.25 (0.62-2.51) 1.30 (0.61-2.79)
    Normalb 155 1.00 (reference) 1.00 (reference) 97 1.00 (reference) 1.00 (reference)
    High (>2-fold) 97 0.98 (0.62-1.54) 0.97 (0.60-1.55) 60 1.75 (0.82-3.72) 2.24 (0.95-5.25)
a  Adjusted for age, sex, race/ethnicity, smoking status, primary tumor site, and AJCC stage group
b Tumor expression >0.5-fold and < 2-fold was considered to be within normal range
5-year Overall Survival (OS)                                   
(N = 439)
3-year Relapse-Free Survival (RFS)                       
(N = 272)
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